뉴모라 테라퓨틱스(NMRA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.73 (-3.20%), 시가총액 $0.34B, 52주 최저~최고 $0.68 ~ $3.59.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addi
뉴모라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
뉴모라 테라퓨틱스의 현재 주가는 $0.73 (-3.20%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
뉴모라 테라퓨틱스의 시가총액은 약 $0.34B입니다.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in t